Edward A Fox

US Patent:

7383135, Jun 3, 2008

Filed:

Nov 3, 2000

Appl. No.:

09/706128

Inventors:

Xiaoling Xie - Cambridge MA, US
Yong Gu - Brookline MA, US
William Markland - Milford MA, US
Michael S Su - Newton MA, US
Paul R Caron - Malden MA, US
Edward Fox - Maynard MA, US
Keith P Wilson - Hopkinton MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

G01N 33/48
G01N 33/50
G06F 19/00
C07K 17/00

US Classification:

702 27, 530350, 435 71, 702 19

Abstract:

The present invention relates to a data storage medium encoded with the corresponding structure coordinates of molecules and molecular complexes which comprise the active site-binding pockets of JNK3. A computer comprising such data storage material is capable of displaying such molecules and molecular complexes, or their structural homologues, as a graphical three-dimensional representation on a computer screen. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen and design compounds, including inhibitory compounds, that bind to JNK3 or homologues thereof. This invention also relates to molecules and molecular complexes which comprise the active site binding pockets of JNK3 or close structural homologues of the active site binding pockets.

US Patent:

8002891, Aug 23, 2011

Filed:

Apr 25, 2008

Appl. No.:

12/150328

Inventors:

Xiaoling Xie - Cambridge MA, US
Yong Gu - Brookline MA, US
William Markland - Milford MA, US
Michael S. Su - Newton MA, US
Paul R. Caron - Malden MA, US
Edward Fox - Maynard MA, US
Keith P. Wilson - Hopkinton MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

C30B 11/00
C30B 7/00
C12N 9/12

US Classification:

117 11, 117 68, 435194

Abstract:

The present invention relates to molecules and molecular complexes which comprise the active site binding pockets of JNK3 or close structural homologues of the active site binding pockets.

US Patent:

20030028417, Feb 6, 2003

Filed:

May 2, 2002

Appl. No.:

10/137524

Inventors:

Edward Fox - Dallas TX, US

International Classification:

G06F017/60

US Classification:

705/010000

Abstract:

The present invention comprises a novel business method for evaluating prospective commercial retail sites. The present invention assists in the evaluation and assessment of prospective sites by forecasting revenues and assessing impact on existing retail establishments. The present invention is also adaptable to forecasting the effects of closing a remotely located retail store based upon on the revenues of another existing store. The present invention overcomes many of the disadvantages of prior art more accurately correlating syndicated panel data to larger population groups.

US Patent:

20030188326, Oct 2, 2003

Filed:

Jun 6, 2002

Appl. No.:

10/165099

Inventors:

Alan D'Andrea - Winchester MA, US
Toshiyasu Taniguchi - Boston MA, US
Cynthia Timmers - Columbus OH, US
Markus Grompe - Portland OR, US
Edward Fox - Boston MA, US

Assignee:

Dana Farber Cancer Institute

International Classification:

A01K067/00
C12Q001/68
G01N033/574
C07H021/04
C12N009/64
C12P021/02
C12N005/06

US Classification:

800/008000, 435/006000, 435/007230, 435/069100, 435/320100, 435/325000, 435/226000, 536/023200

Abstract:

Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway.

US Patent:

20110257036, Oct 20, 2011

Filed:

Mar 29, 2010

Appl. No.:

12/749419

Inventors:

Alan D. D'Andrea - Winchester MA, US
Toshiyasu Taniguchi - Boston MA, US
Cynthia Timmers - Columbus OH, US
Markus Grompe - Portland OR, US
Edward A. Fox - Boston MA, US

Assignee:

Dana Farber Cancer Institute, Inc. - Boston MA

International Classification:

C40B 30/06
G01N 33/566
C12N 5/071
C07K 14/47
C12Q 1/02

US Classification:

506 10, 530350, 435 29, 435375, 435 71

Abstract:

Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway.

US Patent:

20130157294, Jun 20, 2013

Filed:

Oct 17, 2012

Appl. No.:

13/654243

Inventors:

Oregon Health and Science University - Portland OR, US
Edward A. Fox - Boston MA, US
Cynthia Timmers - Columbus OH, US
Markus Grompe - Portland OR, US

Assignee:

Oregon Health and Science University - Portland OR
Dana-Farber Cancer Institute, Inc. - Boston MA

International Classification:

G01N 33/68
C12Q 1/02

US Classification:

435 792, 435 71, 435 29

Abstract:

Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway.

US Patent:

47491175, Jun 7, 1988

Filed:

Apr 1, 1986

Appl. No.:

6/846966

Inventors:

Renato R. Noe - Union City NJ
Edward A. Fox - Glen Mills PA

Assignee:

Public Service Electric and Gas Company - Newark NJ
ICI Americas, Inc. - Wilmington DE

International Classification:

B23K 2008

US Classification:

228107

Abstract:

An improved method for the explosive expansion and welding of tubes to tube sheet includes trepanning the rear face of the tube sheet to form integral collars around each tube-receiving bore in the tube sheet. The collars prevent accumulation of corrosive material in a gap between the tube and tube sheet bore, and provide support to the tube wall when the tube is explosively expanded beyond the region of the tube surrounded by the collar.

US Patent:

20160084821, Mar 24, 2016

Filed:

Oct 21, 2014

Appl. No.:

14/520055

Inventors:

- Boston MA, US
- Portland OR, US
Edward A. Fox - Boston MA, US
Cynthia Timmers - Columbus OH, US
Markus Grompe - Portland OR, US

International Classification:

G01N 33/50

Abstract:

Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway.